RecruitingNCT07420543

Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach

Sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Enrollment

30 participants

Start Date

Jan 18, 2017

Study Type

OBSERVATIONAL

Conditions

Glioblastoma Glioblastoma (GBM)Glioblastoma - Category Brain Tumors and/or Solid Tumors Including

Summary

Glioblastoma (GBM) is the most common and lethal primary brain tumor. Identifying blood biomarkers that reflect the tumor's status is a major unmet need for optimal clinical management. 5-ALA (5-Aminolevulinic Acid) administration leads to the accumulation of fluorescent Protoporphyrin IX (PpIX) in GBM cells, allowing identification during surgery. This project aims to leverage 5-ALA induced fluorescence to maximize the informational power of plasma liquid biopsy as a tool for diagnosis, post-treatment follow-up, and as a prognostic tool in patients with GBM.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects blood samples before and after brain tumor surgery to test whether liquid biopsy — detecting tumor DNA fragments in the bloodstream — can track glioblastoma (a highly aggressive brain cancer). Surgery uses a fluorescent dye called 5-ALA that makes tumor tissue glow pink to help surgeons remove more of it. **You may be eligible if...** - You are 18 or older - You have a confirmed or suspected glioblastoma (grade 4 brain tumor) at its first occurrence - Your tumor is in the upper brain (supratentorial) and accessible for surgery - You are suitable for fluorescence-guided surgery with 5-ALA **You may NOT be eligible if...** - You have had prior treatment for this tumor - You are not a candidate for surgery - You have conditions preventing 5-ALA use Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07420543

Related Trials

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

NCT071955914 locations

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT073265664 locations

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NCT074649253 locations

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT0655656393 locations